22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

Grants and Contracts Details

StatusActive
Effective start/end date1/23/2311/2/24

Funding

  • Merck Sharp & Dohme Corporation: $32,546.00